Discover investment opportunities in Psychedelic Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Psychedelic Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Psychedelic Stocks using our Smart AI Filter.
7 stocks found for "Psychedelic Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.02 | ±100.0% | -0.3 | 0.00% | |||
1.95 | ±75.5% | -1.5 | 0.00% | |||
0.49 | ±66.7% | -1.1 | 0.00% | |||
1.28 | ±88.5% | -5.2 | 0.00% | |||
1.17 | ±100.0% | -4.1 | 0.00% | |||
0.59 | ±31.6% | 34.5 | 0.77% | |||
0.82 | ±100.0% | -13.0 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
atai Life Sciences (ATAI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Read moreThe consensus price target hints at an 831.4% upside potential for Cybin Inc. (CYBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read moreQ: How have psychedelic stocks like MNMD and CMPS performed historically in volatile markets?
A: Psychedelic stocks, including MNMD and CMPS, often exhibit high volatility due to their emerging industry status and regulatory uncertainties. Historically, these stocks have seen significant fluctuations influenced by clinical trial news and legislative changes.
Q: Are companies like ATAI involved in psychedelic research offering dividends?
A: ATAI, similar to other psychedelic research companies, primarily focuses on growth and reinvestment. Most do not offer dividends as they allocate resources toward R&D and expanding their therapeutic pipelines.
Q: What sectors are impacted by the growth of psychedelic stocks like RLMD and CYBN?
A: Psychedelic stocks like RLMD and CYBN primarily impact the healthcare and biotechnology sectors. Their potential breakthrough treatments for mental health conditions influence market dynamics and investor interest in these fields.
Q: Do psychedelic stocks like GHRS and CYBN show any potential for ESG investment?
A: While psychedelic stocks like GHRS and CYBN may not traditionally focus on ESG factors, they pursue innovations in mental health treatment, aligning with social impact goals. Investors consider their therapeutic potential as a positive societal contribution.
Q: How does geographic location affect the psychedelic stocks like MYCOF?
A: MYCOF, a Canadian company, benefits from Canada's progressive stance on psychedelic research, providing a supportive regulatory environment. Geographic location affects their access to financing, research opportunities, and market expansion.
Q: What are the risks associated with investing in early-stage psychedelic companies like ENOB?
A: ENOB, as an early-stage psychedelic company, faces risks including regulatory hurdles, high research and development costs, potential clinical trial failures, and market competition influencing stock performance.